var data={"title":"Fat emulsion: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fat emulsion: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6181?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fat-emulsion-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fat emulsion: Patient drug information&quot;</a> and <a href=\"topic.htm?path=fat-emulsion-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fat emulsion: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708777\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Deaths in preterm infants:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Deaths in preterm infants after infusion of intravenous (IV) fat emulsions have been reported. Autopsy findings included intravascular fat accumulation in the lungs. Treatment of premature and low-birth-weight infants with IV fat emulsion must be based on careful benefit-risk assessment. Strict adherence to the recommended total daily dose is mandatory; hourly infusion rate should be as slow as possible. Preterm infants and low birth weight infants and small for gestational age infants have poor clearance of IV fat emulsion and increased free fatty acid plasma levels following fat emulsion infusion; therefore, serious consideration must be given to administration of less than the maximum recommended doses in these patients to decrease the likelihood of IV fat overload. Monitor the infant's ability to eliminate the infused fat from the circulation (such as triglycerides and/or plasma free fatty acid levels). The lipemia must clear between daily infusions.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170060\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Intralipid;</li>\n      <li>Liposyn III [DSC];</li>\n      <li>Nutrilipid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170061\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Intralipid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170074\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Caloric Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170062\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> At the onset of therapy, the patient should be observed for any immediate allergic reactions (eg, dyspnea, cyanosis, and fever).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Caloric source:</b> IV: <b>Note:</b> Fat emulsion should not exceed 60% of the total daily calories.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial dose: 1 to 1.5 g/kg/day (not to exceed 500 mL Intralipid 10% or 20% or 330 mL Intralipid 30% [over 4 to 6 hours] on the first day of therapy); daily dose may be infused over 12 to 24 hours; maximum daily dose: 2.5 g/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Essential fatty acid deficiency (EFAD), prevention:</b> IV: Administer at least 2% to 4% of total caloric intake as linoleic acid and 0.25% to 0.5% as alpha linolenic acid (Mirtallo 2004; Mirtallo 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Essential fatty acid deficiency (EFAD), treatment:</b> Intralipid: IV: Administer 8% to 10% of total caloric intake as fat emulsion; may infuse up to once daily (Riella 1975). If EFAD occurs with stress, the dosage needed to correct EFAD may be increased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Serious hemodynamic or other instability secondary to highly lipid soluble substances (off-label use):</b> <b>Note: </b>Continue chest compressions during administration (lipid must circulate): 20%: IV: 1.5 <b>mL</b>/kg administered over 1 to 3 minutes, followed immediately by an infusion of 0.25 <b>mL</b>/kg/minute (recommended infusion durations vary; see below); may repeat the bolus as necessary for persistent cardiovascular collapse or if instability re-emerges (ACMT 2016; AHA [Lavonas 2015]; ASRA [Neal 2012]). Some suggest dosing based on lean body weight (AHA [Lavonas 2015]; ASRA [Neal 2012]). Suggested maximum dose: 10 <b>mL</b>/kg over the first 30 to 60 minutes (AHA [Lavonas 2015]; ASRA [Neal 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">After administration of the initial bolus and continuous infusion, recommendations regarding the continuous infusion vary significantly:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>American College of Medical Toxicology: </i>If after the bolus and continuing the infusion for 3 minutes the patient demonstrates a significant response, the infusion rate may be reduced to 0.025 <b>mL</b>/kg/minute (ie, one-tenth the initial rate). If instability re-emerges, the infusion rate may be increased back to 0.25 <b>mL/</b>kg/minute <b>or </b>the bolus may be repeated (ACMT 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>American Heart Association recommendations: </i>Continue infusion for 30 to 60 minutes (AHA [Lavonas 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>American Society of Regional Anesthesia and Pain Medicine: </i>Continue infusion for at least 10 minutes after hemodynamic stability has been restored. Increase the infusion rate to 0.5 <b>mL</b>/kg/minute if hemodynamic instability persists or recurs. (ASRA [Neal 2012])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170069\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=fat-emulsion-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fat emulsion: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> At the onset of therapy, the patient should be observed for any immediate allergic reactions (eg, dyspnea, cyanosis, and fever).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Caloric source:</b> IV: <b>Note:</b> Fat emulsion should not exceed 60% of the total daily calories.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: Initial dose: 1 to 2 g/kg/day, increase by 0.5 to 1 g/kg/day to a maximum of 3 g/kg/day depending on needs/nutritional goals; daily dose may be infused over 24 hours (ASPEN Guidelines 2002; ASPEN Pediatric Nutrition Support Core Curriculum 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to 10 years of age: Initial dose: 1 to 2 g/kg/day, increase by 0.5-1 g/kg/day to a maximum of 2 to 3 g/kg/day depending on needs/nutritional goals; daily dose may be infused over 24 hours (ASPEN Guidelines, 2002; ASPEN Pediatric Nutrition Support Core Curriculum 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Initial dose: 1 g/kg/day (not to exceed 500 mL Intralipid 10% or 20% or 330 mL Intralipid 30% [over 4 to 6 hours] on the first day of therapy); increase by 1 g/kg/day to a maximum of 2.5 g/kg/day depending upon the needs/nutritional goals; daily dose may be infused over 12 to 24 hours (ASPEN Guidelines 2002; ASPEN Pediatric Nutrition Support Core Curriculum 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Essential fatty acid deficiency (EFAD), prevention:</b> IV: Children and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Essential fatty acid deficiency (EFAD), treatment:</b> IV: Intralipid: Children and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170063\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24036960\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24036961\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170047\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intralipid: 20% (100 mL, 250 mL, 500 mL, 1000 mL); 30% (500 mL) [contains egg yolk phospholipids, glycerin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Liposyn III: 30% (500 mL [DSC]) [contains egg phosphatides]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nutrilipid: 20% (250 mL, 500 mL, 1000 mL) [contains egg yolk phospholipids, glycerin]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170033\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22625968\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Product oil source for Intralipid and Nutrilipid: soybean</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50306587\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Emulsion, Intravenous:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intralipid: 10% (100 mL, 250 mL, 500 mL, 1000 mL); 30% (250 mL, 333 mL, 1000 mL) [contains egg phospholipids, glycerol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170049\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer by IV infusion only via peripheral line or by central venous infusion. All fat emulsion infusions should be filtered whether part of an admixture or infused separately using a 1.2-micron in-line filter only (ISMP 2016). At the onset of therapy, the patient should be observed for any immediate allergic reactions such as dyspnea, cyanosis, and fever. Change tubing after each infusion. May be simultaneously infused with carbohydrate/amino acid solutions by means of Y-connector located near infusion site or administered in total nutrient mixtures (3-in-1) with amino acids, dextrose, and other nutrients. Fat emulsions of 30% should only be administered in total nutrient mixtures (3-in-1) with amino acids, dextrose, and other nutrients. Hang fat emulsion higher than other fluids (has low specific gravity and could run up into other lines).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intralipid: Prior to opening the overwrap, the integrity indicator should be inspected. If the indicator is black, the overwrap is damaged; do not use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nutrilipid: To avoid air embolism, use a nonvented infusion set or close the air vent on a vented set and use a dedicated line without any connections. Prior to opening the overwrap, the oxygen indicator should be inspected; if the indicator is pink or dark pink, do not use. May be infused concurrently into the same vein as carbohydrate-amino acid solutions by means of a Y-connector located near the infusion site; flow rates of each solution should be controlled separately by infusion pumps. Do not use administration sets and lines that contain di-2-ethylhexyl phthalate (DEHP). See prescribing information for detailed administration information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Caloric source/EFAD:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: Initiate infusions of 10% emulsions at &le;0.1 mL/minute for 10 to 15 minutes; if no untoward effects occur, the infusion rate may be increased to 1 mL/kg/hour (maximum rate: 100 mL/hour). Initiate infusions of 20% emulsions at &le;0.05 mL/minute for 10 to 15 minutes; if no untoward effects occur, the infusion rate may be increased to 0.5 mL/kg/hour. <b>Note:</b> Premature and/or septic infants may require reduced infusion rates. Do not exceed 1 g fat/kg in 4 hours in this population.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Initiate infusions of 10% emulsions at 1 mL/minute for 15 to 30 minutes; if no untoward effects occur, the infusion rate may be increased to 2 mL/minute. Initiate infusions of 20% emulsions at 0.5 mL/minute for 15 to 30 minutes; if no untoward effects occur, the infusion rate may be increased to 1 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Serious hemodynamic or other instability secondary to highly lipid soluble substances (off-label use):</i> Administer initial bolus over 1 to 3 minutes followed by a continuous infusion. Chest compressions should continue during administration if patient is in cardiac arrest. Some experts recommend a decreased infusion rate in patients who respond favorably to the initial bolus and infusion (ACMT 2016); repeat bolus or an increase in the infusion rate may be considered if instability persists or recurs. (ACMT, 2016; AHA [Lavonas 2015]; ASRA [Neal 2012]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170048\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Caloric/fatty acid source:</b> Source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for longer than 5 days) or when oral or enteral nutrition is not possible, insufficient, or contraindicated; to prevent and treat essential fatty acid deficiency (except Nutrilipid).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725585\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Serious hemodynamic or other instability secondary to highly lipid soluble substances</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14599185\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intralipid may be confused with ViperSlide (lubricant used during atherectomy procedures)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170040\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Cholestasis (central lobular), melanosis (brown fat pigmentation in the reticuloendothelial system)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia, splenomegaly, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatomegaly, increased liver enzymes, overloading syndrome (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Back pain, chest pain, cyanosis, diaphoresis, dizziness, drowsiness, dyspnea, flushing, headache, hypercoagulability state, hyperlipidemia, hypersensitivity reaction, increased body temperature, infusion site irritation, nausea, sensation of eye pressure, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170052\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intralipid 20%, 30%: Disturbances in normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if accompanied by hyperlipidemia; pharmacy bulk package is not intended for direct IV administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nutrilipid: Known hypersensitivity to egg or soybean proteins or to any component of the formulation; severe hyperlipidemia (serum triglyceride concentrations above 1,000 mg/dL) or severe disorders of lipid metabolism characterized by hypertriglyceridemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to egg, soya or peanut protein or to any component of the formulation; acute shock; severe hyperlipidemia; conditions characterized by severely disordered fat metabolism (eg, severe hepatic impairment, acute MI, hemophagocytotic syndrome, shock)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170037\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:0em;\">\n      <b>\n        <i>Concerns related to adverse effects</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fat overload syndrome: Although rare, a reduced or limited ability to metabolize lipids accompanied by prolonged plasma clearance resulting in a sudden deterioration in the patient's condition accompanied by fever, anemia, leukopenia, thrombocytopenia, coagulation disorders, hyperlipidemia, liver fatty infiltration (hepatomegaly), deteriorating liver function, and CNS (eg, coma) can occur; usually reversible upon discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Parenteral nutrition: Although the exact etiology is unknown and likely multifactorial, parenteral nutrition associated liver disease (PNALD) has been reported in patients receiving parenteral nutrition for extended periods of time, especially preterm infants, and can present as cholestasis or steatohepatitis, fibrosis and cirrhosis, possibly leading to hepatic failure; cholecystitis and cholelithiasis have also been observed. Consider discontinuation or dose reduction in patients who develop abnormal LFTs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Allergic reactions (eg, tachypnea, dyspnea, hypoxia, bronchospasm, tachycardia, vomiting, headache, sweating) to lipid emulsion may occur; discontinue infusion immediately if signs or symptoms of hypersensitivity or allergic reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Refeeding syndrome: Parenteral nutrition: Refeeding severely undernourished patients with parenteral nutrition may result in the refeeding syndrome (eg, intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic); thiamine deficiency and fluid retention may also develop. Carefully monitor severely undernourished patients and slowly increase their nutrient intakes, while avoiding overfeeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anemia: The use of fat emulsion has been associated with anemia likely due to hemodilution (Zellner 1967). Use with caution in patients with anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fat embolism: Use with caution in patients who may be at danger for fat embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Use with caution in patients with pancreatitis without hyperlipidemia; ensure triglyceride levels remain &lt;400 mg/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution; some formulations may contain aluminum, which may accumulate following prolonged administration in renally impaired patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Toxicity secondary to highly lipid soluble substances: Hemodynamic and other instability: Successful resuscitation following the administration of fat emulsion has been reported in animal studies and several human case reports in which cardiovascular toxicity was unresponsive to conventional resuscitation and antidotal measures. Successful resuscitation following the administration of fat emulsion has been reported in pediatric patients (Fuzaylov 2010; Ludot 2008; Shah 2009; Wong 2010). Additional information is available at http://www.lipidrescue.org. Consider use when toxicity secondary to a highly lipid soluble substance is likely and conventional methods are unsuccessful. Continue CPR throughout treatment with lipid emulsion. Consultation with a medical toxicologist or poison control center is highly recommended.</p>\n    <p style=\"text-indent:0em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: <b>[US Boxed Warning]: Deaths in preterm infants following administration of fat emulsion have been reported; autopsy findings included intravascular fat accumulation in the lungs. Premature infants, low birth weight infants, and small for gestational age infants clear intravenous fat emulsion poorly and have increased free fatty acid plasma levels following fat emulsion infusion. Strict adherence to proper infusion rates, dosing, and monitoring are necessary; infusion rate should be as slow as possible; strict monitoring of metabolic tolerance and elimination of infused fat from the circulation must occur.</b> To avoid hyperlipidemia and/or fat deposition, do not exceed recommended daily doses and consider administering less than the maximum recommended doses in preterm and small for gestational age infants. Because free fatty acids displace bilirubin from albumin binding sites, the use of lipid infusions in jaundiced or premature infants should be done with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: The too-rapid administration of fat emulsion can cause fluid and/or fat overloading, resulting in dilution of serum electrolyte concentrations, overhydration, congested states, pulmonary edema, impaired pulmonary diffusion capacity, or metabolic acidosis; hourly infusion rate should be as low as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Three-in-one mixtures: Lipid emulsion in a three-in-one mixture may obscure the presence of a precipitate; follow compounding guidelines, especially for calcium and phosphate additions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170043\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5062137\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Indications for fat emulsion therapy in pregnant women are the same as in nonpregnant women. The ASPEN guidelines for parenteral and enteral nutrition state that intravenous fat emulsion may be used safely in pregnant women to provide calories and prevent essential fatty acid deficiency (ASPEN Guidelines 2002). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015). Lipid emulsion therapy has been used successfully in the resuscitation of a pregnant female with suspected bupivacaine toxicity (Spence 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13824136\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if fat emulsion (plant based) is excreted in breast milk. The fatty acids found in fat emulsion (eg, linoleic acid, linolenic acid) are endogenous to human milk and concentrations are influenced by maternal diet (IOM 2005). According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5020936\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Phosphorus: ~1.5 mMol /100 mL of emulsion</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Caloric content: 10% fat emulsion = 1.1 kcal/mL; 20% fat emulsion = 2 kcal/mL; 30% fat emulsion = 3 kcal/mL</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Fat emulsion should not exceed 60% of the total daily calories.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170045\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;\">Monitor for signs and symptoms of infection (including vascular access device complications); fluid and electrolyte status; serum osmolarity; blood glucose; blood counts (including platelets and coagulation parameters); signs and symptoms of essential fatty acid deficiency, refeeding syndrome,  and/or hypersensitivity reactions.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Monitor liver and renal function tests periodically. Monitor triglycerides before initiation of lipid therapy and at least weekly during therapy (or until triglycerides are stable and when changes are made in the amount of fat administered; ASPEN Guidelines, 2002); monitor especially closely in premature infants, septic infants, and patients with pancreatitis or liver disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170036\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fat emulsion is metabolized and utilized as an energy source; provides the essential fatty acids, linoleic acid, and alpha linolenic acid necessary for normal structure and function of cell membranes;  in local anesthetic toxicity, lipid emulsion probably extracts lipophilic local anesthesia from cardiac muscle</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In toxicity secondary to highly lipid soluble substances, exogenous lipids provide an alternative source of binding (Rowlingson 2008), commonly known as the &quot;lipid sink&quot; effect. High lipid partition constant and large volumes of distribution are good predictors of success when using lipid therapy (French 2011). Lipid administration may also affect the heart in a metabolically advantageous way by improving fatty acid transport (Weinberg 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170051\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Fatty acids, phospholipids, and glycerol are metabolized by cells to adenosine triphosphate (ATP), carbon dioxide, and water</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 0.5 to 1 hour</p>\n    <p style=\"text-indent:0em;\">Excretion: Biliary (phospholipids)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323146\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Emulsion</b> (Intralipid Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20% (250 mL): $49.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30% (500 mL): $65.13</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170054\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Intrafat (TW);</li>\n      <li>Intralipid (AE, AU, BG, BH, CH, CN, CY, CZ, DK, EE, EG, ES, FI, HK, HU, ID, IL, IN, IQ, IR, IS, JO, KR, KW, LK, LT, LU, LY, MT, MY, NL, NO, NZ, OM, PH, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SY, TH, TR, UA, YE);</li>\n      <li>Intralipide (FR);</li>\n      <li>Intralipos (KR, MY, TH, TW);</li>\n      <li>Lipofundin-S (MY, TW);</li>\n      <li>Liposyn II (MX, PE);</li>\n      <li>Lipovenos (CL, PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR &sect;201.323.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27121236\"></a>American College of Medical Toxicology (ACMT). ACMT Position Statement: Guidance for the Use of Intravenous Lipid Emulsion [published online ahead of print]. <i>J Med Toxicol. </i>2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/27121236/pubmed\" target=\"_blank\" id=\"27121236\">27121236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients. <i>JPEN J Parenter Enteral Nutr</i>, 2002, 26(1)(suppl):1-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/11841046/pubmed\" target=\"_blank\" id=\"11841046\">11841046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23186600\"></a>Arora NP, Berk WA, Aaron CK, Williams KA. Usefulness of intravenous lipid emulsion for cardiac toxicity from cocaine overdose. <i>Am J Cardiol</i>. 2013;111(3):445-447.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/23186600/pubmed\" target=\"_blank\" id=\"23186600\">23186600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carney LN, Nepa A, Cohen SS, et al, &ldquo;Parenteral and Enteral Nutrition Support: Determining the Best Way to Feed,&rdquo; In: Corkins MR, Balint J, Bobo E, et al, eds, <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>, Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2010, 440.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Carr.2009\"></a>Carr D, Boone A, Hoffman RS, et al. Successful resuscitation of a carvedilol overdose using intravenous fat emulsion. <i>Clin Toxicol</i>. 2009;47(7):727.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Carr.2009.1\"></a>Carr D, Boone A, Hoffman RS, et al. Successful resuscitation of a carvedilol overdose using intravenous fat emulsion. <i>Clin Toxicol</i>. 2009;47(7):710.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21621362\"></a>Castanares-Zapatero D, Wittebole X, Huberlant V, Morunglav M, Hantson P. Lipid emulsion as rescue therapy in lamotrigine overdose. <i>J Emerg Med</i>. 2012;42(1):48-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/21621362/pubmed\" target=\"_blank\" id=\"21621362\">21621362</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19892505\"></a>Cohen V, Jellinek SP, Stansfield L, Truong H, Baseluos C, Marshall JP. Cardiac arrest with residual blindness after overdose of Tessalon (benzonatate) perles [published online November 5, 2009]. <i>J Emerg Med</i>. 2011;41(2):166-171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/19892505/pubmed\" target=\"_blank\" id=\"19892505\">19892505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corcoran W, Butterworth J, Weller RS, et al, &ldquo;Local Anesthetic-Induced Cardiac Toxicity: A Survey of Contemporary Practice Strategies Among Academic Anesthesiology Departments,&rdquo; <i>Anesth Analg</i>, 2006, 103(5):1322-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/17056977/pubmed\" target=\"_blank\" id=\"17056977\">17056977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21068706\"></a>Dagtekin O, Marcus H, M&uuml;ller C, B&ouml;ttiger BW, Sp&ouml;hr F. Lipid therapy for serotonin syndrome after intoxication with venlafaxine, lamotrigine and diazepam. <i>Minerva Anestesiol.</i> 2011;77(1):93-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/21068706/pubmed\" target=\"_blank\" id=\"21068706\">21068706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21263316\"></a>Dix SK, Rosner GF, Nayar M, et al. Intractable cardiac arrest due to lidocaine toxicity successfully resuscitated with lipid emulsion. <i>Crit Care Med</i>. 2011;39(4):872-874.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/21263316/pubmed\" target=\"_blank\" id=\"21263316\">21263316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19143698\"></a>Finn SD, Uncles DR, Willers J, Sable N. Early treatment of a quetiapine and sertraline overdose with Intralipid. <i>Anaesthesia</i>. 2009;64(2):191-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/19143698/pubmed\" target=\"_blank\" id=\"19143698\">19143698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17448066\"></a>Foxall G, McCahon R, Lamb J, et al, &ldquo;Levobupivacaine-Induced Seizures and Cardiovascular Collapse Treated With Intralipid,&rdquo; <i>Anaesthesia</i>, 2007, 62(5):516-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/17448066/pubmed\" target=\"_blank\" id=\"17448066\">17448066</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21320947\"></a>Franxman TJ, Al-Nabhan M, Cavallazzi RS, Speak AJ. Lipid emulsion therapy for verapamil overdose. <i>Ann Intern Med</i>. 2011;4(4):292.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/21320947/pubmed\" target=\"_blank\" id=\"21320947\">21320947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21563913\"></a>French D, Armenian P, Ruan W, Wong A, Drasner K, Olson KR, Wu AH. Serum verapamil concentrations before and after Intralipid therapy during treatment of an overdose. <i>Clin Toxicol (Phila).</i> 2011a;49(4):340-344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/21563913/pubmed\" target=\"_blank\" id=\"21563913\">21563913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21981684\"></a>French D, Smollin C, Ruan W, et al. Partition Constant and Volume of Distribution as Predictors of Clinical Efficacy of Lipid Rescue for Toxicological Emergencies. <i>Clin Toxicol.</i> 2011b;49(9):801-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/21981684/pubmed\" target=\"_blank\" id=\"21981684\">21981684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuzaylov G, Ying B, Tang Y, Sethna NF. Successful resuscitation after inadvertent intravenous injection of bupivacaine in an adolescent. <i>Paediatr Anaesth</i>. 2010;20(10):958-959.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21989640\"></a>Geib AJ, Liebelt E, Manini AF; Toxicology Investigators&rsquo; Consortium (ToxIC). Clinical experience with intravenous lipid emulsion for drug-induced cardiovascular collapse. <i>J Med Toxicol</i>. 2012;8(1):10-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/21989640/pubmed\" target=\"_blank\" id=\"21989640\">21989640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haumont D, Richelle M, Deckelbaum RJ, et al, &ldquo;Effect of Liposomal Content of Lipid Emulsions of Plasma Lipid Concentrations in Low Birth Weight Infants Receiving Parenteral Nutrition,&rdquo; <i>J Pediatr</i>, 1992, 121(5 Pt 1):759-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/1432430/pubmed\" target=\"_blank\" id=\"1432430\">1432430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20090535\"></a>Hillyard SG, Barrera-Groba C, Tighe R. Intralipid reverses coma associated with zopiclone and venlafaxine overdose<i>. Eur J Anaesthesiol</i>. 2010;27(6):582-583.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/20090535/pubmed\" target=\"_blank\" id=\"20090535\">20090535</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Intralipid 20% (IV fat emulsion) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Intralipid 30% (IV fat emulsion) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; April 2000.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Intralipid (IV fat emulsion) [product monograph]. Toronto, Ontario, Canada: Fresenius Kabi Canada; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients)</i>, Washington, DC: The National Academies Press, 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IV fat emulsion needs a filter.<i> ISMP Medication Safety Alert! Acute Care Edition</i>. 2016;21(1):3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22074030\"></a>Jakkala-Saibaba R, Morgan PG, Morton GL. Treatment of cocaine overdose with lipid emulsion. <i>Anaesthesia</i>. 2011;66(12):1168-1170.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/22074030/pubmed\" target=\"_blank\" id=\"22074030\">22074030</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/26443610/pubmed\" target=\"_blank\" id=\"26443610\">26443610</a>]</span><span class=\"doi\">10.1161/CIR.0000000000000300</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21740142\"></a>Jovic-Stosic J, Gligic B, Putic V, Brajkovic G, Spasic R. Severe propranolol and ethanol overdose with wide complex tachycardia treated with intravenous lipid emulsion: a case report. <i>Clin Toxicol (Phila)</i>. 2011;49(5):426-340.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/21740142/pubmed\" target=\"_blank\" id=\"21740142\">21740142</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24197589\"></a>Kundu R, Almasri H, Moza A, Ghose A, Assaly R. Intravenous lipid emulsion in wide complex arrhythmia with alternating bundle branch block pattern from cocaine overdose. <i>Kardiol Pol</i>. 2013;71(10):1073-1075.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/24197589/pubmed\" target=\"_blank\" id=\"24197589\">24197589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26472998\"></a>Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care [published erratum appears in <i>Circulation</i>. 2016;134(9):e122.] <i>Circulation</i>. 2015;132(18)(suppl 2):S501-S518.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/26472998/pubmed\" target=\"_blank\" id=\"26472998\">26472998</a>]</span><span class=\"doi\">10.1161/CIR.0000000000000264</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21854635\"></a>Liang CW, Diamond SJ, Hagg DS. Lipid rescue of massive verapamil overdose: a case report. <i>J Med Case Rep</i>. 2011;5:399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/21854635/pubmed\" target=\"_blank\" id=\"21854635\">21854635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16867094\"></a>Litz RJ, Popp M, Stehr SN, et al, &ldquo;Successful Resuscitation of a Patient With Ropivacaine-Induced Asystole After Axillary Plexus Block Using Lipid Infusion,&rdquo; <i>Anaesthesia</i>, 2006, 61(8):800-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/16867094/pubmed\" target=\"_blank\" id=\"16867094\">16867094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Lu.2009\"></a>Lu JJ, Hast HA, Erickson TB. Dramatic QTc narrowing after intralipid administration in quetiapine overdose. <i>Clin Toxicol</i>. 2009;47(7):740.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ludot H, Tharin JY, Belouadah M, et al, &quot;Successful Resuscitation After Ropivacaine and Lidocaine-Induced Ventricular Arrhythmia Following Posterior Lumbar Plexus Block in a Child,&quot; <i>Anesth Analg</i>, 2008, 106(5):1572-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/18420879/pubmed\" target=\"_blank\" id=\"18420879\">18420879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo J, Canada T, Johnson D, et al, &ldquo;Safe Practices for Parenteral Nutrition. Task Force for the Revision of Safe Practices for Parenteral Nutrition,&rdquo; <i>JPEN J Parenter Enteral Nutr</i>, 2004, 28(6):S39-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/15568296/pubmed\" target=\"_blank\" id=\"15568296\">15568296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo JM, Dasta JF, Kleinschmidt KC, et al, &ldquo;State of the Art Review: Intravenous Fat Emulsions: Current Applications, Safety Profile, and Clinical Implications,&rdquo; <i>Ann Pharmacother</i>, 2010, 44(4):688-700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/20332339/pubmed\" target=\"_blank\" id=\"20332339\">20332339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21088599\"></a>Montiel V, Gougnard T, Hantson P. Diltiazem poisoning treated with hyperinsulinemic euglycemia therapy and intravenous lipid emulsion. <i>Eur J Emerg Med</i>. 2011;18(2):121-123.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/21088599/pubmed\" target=\"_blank\" id=\"21088599\">21088599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22189574\"></a>Neal JM, Mulroy MF, and Weinberg GL, &ldquo;American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version,&rdquo; <i>Reg Anesth Pain Med</i>, 2012, 37(1):16-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/22189574/pubmed\" target=\"_blank\" id=\"22189574\">22189574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neuzil J, Darlow BA, Inder TE, et al, &ldquo;Oxidation of Parenteral Lipid Emulsion by Ambient and Phototherapy Lights: Potential Toxicity of Routine Parenteral Feeding,&rdquo; <i>J Pediatr</i>, 1995, 126(5 Pt 1):785-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/7752007/pubmed\" target=\"_blank\" id=\"7752007\">7752007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nutrilipid 20% (IV fat emulsion) [prescribing information]. Bethlehem, PA: B. Braun Medical Inc; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Oakes.2009\"></a>Oakes JA, Piquette C, Barthold CL. Successful use of intravenous lipid as adjunctive therapy in a severe calcium channel antagonist poisoning<i>. Clin Toxicol</i>. 2009;47(7):755.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riella MC, Broviac JW, Wells M, Scribner BH. Essential fatty acid deficiency in human adults during total parenteral nutrition. <i>Ann Intern Med</i>. 1975;83(6):786-789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/128309/pubmed\" target=\"_blank\" id=\"128309\">128309</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16810015\"></a>Rosenblatt MA, Abel M, Fischer GW, et al, &ldquo;Successful Use of a 20% Lipid Emulsion to Resuscitate a Patient After a Presumed Bupivacaine-Related Cardiac Arrest,&rdquo; <i>Anesthesiology</i>, 2006, 105(1):217-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/16810015/pubmed\" target=\"_blank\" id=\"16810015\">16810015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlingson JC, &quot;Lipid Rescue: A Step Forward in Patient Safety? Likely So!&quot; <i>Anesth Analg</i>, 2008, 106(5):1333-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/18420839/pubmed\" target=\"_blank\" id=\"18420839\">18420839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shah S, Gopalakrishnan S, Apuya J, Shah S, Martin T. Use of Intralipid in an infant with impending cardiovascular collapse due to local anesthetic toxicity. <i>J Anesth</i>. 2009;23(3):439-441.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17766009\"></a>Sirianni AJ, Osterhoudt KC, Calello DP, et al. Use of lipid emulsion in the resuscitation of a patient with prolonged cardiovascular collapse after overdose of bupropion and lamotrigine. <i>Ann Emerg Med</i>. 2008;51(4):412-415.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/17766009/pubmed\" target=\"_blank\" id=\"17766009\">17766009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spence AG. Lipid reversal of central nervous system symptoms of bupivacaine toxicity. <i>Anesthesiology</i>. 2007;107(3):516-517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/17721262/pubmed\" target=\"_blank\" id=\"17721262\">17721262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19451589\"></a>Weinberg G, Di Gregorio G, Hiller D, Hewett A, Sirianni A. Reversal of haloperidol-induced cardiac arrest by using lipid emulsion. <i>Ann Intern Med</i>. 2009;150(10):737-738.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/19451589/pubmed\" target=\"_blank\" id=\"19451589\">19451589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinberg GL, Ripper R, Murphy P, et al, &ldquo;Lipid Infusion Accelerates Removal of Bupivacaine and Recovery From Bupivacaine Toxicity in the Isolated Rat Heart,&rdquo; <i>Reg Anesth Pain Med</i>, 2006, 31(4):296-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/16857549/pubmed\" target=\"_blank\" id=\"16857549\">16857549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong GK, Joo DT, McDonnell C. Lipid resuscitation in a carnitine deficient child following intravascular migration of an epidural catheter. <i>Anaesthesia</i>. 2010;65(2):192-195.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19282085\"></a>Young AC, Velez LI, Kleinschmidt KC. Intravenous fat emulsion therapy for intentional sustained-release verapamil overdose. <i>Resuscitation.</i> 2009;80(5):591-593.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/19282085/pubmed\" target=\"_blank\" id=\"19282085\">19282085</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zellner DC, Iacono JM. &quot;Dilution anemia&quot; associated with multiple infusions of a fat emulsion. <i>Am J Clin Nutr</i>. 1967;20(7):766-776.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-drug-information/abstract-text/6036266/pubmed\" target=\"_blank\" id=\"6036266\">6036266</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8437 Version 140.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708777\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F170060\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F170061\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F170074\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F170062\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F170069\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F170063\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F24036960\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F24036961\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F170047\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F170033\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F22625968\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50306587\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F170049\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F170048\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725585\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14599185\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F170040\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F170052\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F170037\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F170043\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5062137\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13824136\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F5020936\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F170045\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F170036\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F170051\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323146\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F170054\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8437|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fat-emulsion-patient-drug-information\" class=\"drug drug_patient\">Fat emulsion: Patient drug information</a></li><li><a href=\"topic.htm?path=fat-emulsion-pediatric-drug-information\" class=\"drug drug_pediatric\">Fat emulsion: Pediatric drug information</a></li></ul></div></div>","javascript":null}